ArticleCancer letters2009
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.
Article in Cancer letters, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Enhanced anti-tumor efficacy of tumor-infiltrating lymphocytes by GITR agonist in ovarian cancer.Frontiers in immunology · 2025Article
- Implications of IL-21 in solid tumor therapy.Medical oncology (Northwood, London, England) · 2023Review
- The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- S-15 in combination of Akt inhibitor promotes the expansion of CD45RACancer cell international · 2019Article
- A New Method for Reactivating and Expanding T Cells Specific forMolecular therapy. Methods & clinical development · 2018Article
- T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Pharmacology & therapeutics · 2018Review
- Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma.International journal of molecular sciences · 2017Article
- Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.Cancer immunology, immunotherapy : CII · 2016Article
- Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.Seminars in oncology · 2015Review
- Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma.International journal of molecular sciences · 2015Article
- T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.Human gene therapy methods · 2014Article
- Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.Advances in hematology · 2012Article
- Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy.Journal of translational medicine · 2011Article
- Immunomodulatory cytokines as therapeutic agents for melanoma.Immunotherapy · 2011Review
- IL-21-treated naive CD45RA+ CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype.Cancer immunology, immunotherapy : CII · 2011Article
- Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.Cancer immunology, immunotherapy : CII · 2010Article
- Article
- Redirecting the immune response: role of adoptive T cell therapy.Human gene therapy · 2010Review
- Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.Journal of immunotherapy (Hagerstown, Md. : 1997)Article
- Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Although T central memory cells have been described as the most effective T-cell subtype against tumor growth, little is known about the requirements needed for their optimal ex vivo generation. Hence, our goal is to establish a protocol that will lead to consistent ex vivo generation of lymphocytes skewed toward a central memory phenotype. Antigen-specific T-cell lines were generated by ex vivo stimulation with Class-I and Class-II melanoma peptide pulsed dendritic cells in the presence of either IL-2 or IL-15 plus IL-21. Tumor specific lymphocytes of both central memory and effector characteristics were consistently generated from healthy donors and melanoma patients. IL15/IL21 cultures result in a cell population with a lower proportion of CD4(+)CD25(high)FoxP3(+) regulatory cells and higher number of CD8(+) and CD56(+) cells, and consequently render a higher yield of cells with a greater cytolytic activity and IFN-gamma production against melanoma cell lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.